Tỷ lệ cao của Long COVID ở bệnh nhân suy miễn dịch biến đổi thông thường: Một nghiên cứu đa trung tâm tại Ý
Tóm tắt
Các tác động lâu dài của nhiễm SARS-CoV-2 đại diện cho một vấn đề sức khỏe toàn cầu quan trọng. Long COVID (LC) được định nghĩa là một tổ hợp các dấu hiệu và triệu chứng phát triển trong hoặc sau nhiễm SARS-CoV-2 và kéo dài > 12 tuần. Ở những bệnh nhân suy miễn dịch biến đổi thông thường (CVID), chúng tôi đã báo cáo trước đó về nguy cơ nhập viện và tử vong cao hơn trong thời gian nhiễm SARS-CoV-2, cũng như tình trạng dương tính kéo dài của mẫu và sự tái nhiễm thường xuyên. Mục tiêu của nghiên cứu hiện tại là đánh giá nguy cơ LC ở một nhóm bệnh nhân CVID tại Ý. Chúng tôi sử dụng phiên bản dịch của khảo sát do Trung tâm Kiểm soát và Phòng ngừa Dịch bệnh (CDC) đề xuất để thu thập dữ liệu về LC. Trong nhóm bệnh nhân CVID được tuyển chọn gồm 175 người, chúng tôi phát hiện tỷ lệ cao của LC (65.7%). Các triệu chứng LC phổ biến nhất là mệt mỏi (75.7%), đau khớp/đau cơ (48.7%), và khó thở (41.7%). Phần lớn bệnh nhân (60%) trải qua triệu chứng kéo dài, ít nhất 6 tháng sau khi nhiễm. Trong một phân tích đa biến, sự hiện diện của kiểu hình phức tạp (OR 2.44, 95% CI 1.88–5.03;
Từ khóa
#Long COVID #suy miễn dịch biến đổi thông thường #SARS-CoV-2 #tỷ lệ mắc bệnh #nghiên cứu đa trung tâm #triệu chứng kéo dàiTài liệu tham khảo
Coronavirus disease (COVID-19) situation reports [Internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 22 Dec 2023.
Faghy MA, Owen R, Thomas C, Yates J, Ferraro FV, Skipper L, et al. Is long COVID the next global health crisis? J Glob Health. 2022;12:03067. https://doi.org/10.7189/jogh.12.03067.
Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.656797.
Hanevik K, Wensaas K-A, Rortveit G, Eide GE, Mørch K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59:1394–400. https://doi.org/10.1093/cid/ciu629.
Masood M, Chodisetti S, BaHammam A. Long COVID: the long-term consequences of COVID-19 and the proposed pathophysiological mechanisms. J Nat Sci Med. 2023;6(1):3–11. https://doi.org/10.4103/jnsm.jnsm_133_22.
Post COVID-19 condition [Internet]. Available from: https://www.who.int/teams/health-care-readiness/post-covid-19-condition. Accessed 22 Dec 2023.
Post COVID-19 condition (long COVID) [Internet]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition. Accessed 22 Dec 2023
Ford ND. Long COVID and significant activity limitation among adults, by age — United States, June 1–13, 2022, to June 7–19, 2023. MMWR Morb Mortal Wkly Rep [Internet]. 2023;72. Available from: https://www.cdc.gov/mmwr/volumes/72/wr/mm7232a3.htm. Accessed 22 Dec 2023
Alghamdi HY, Alrashed AM, Jawhari AM, Abdel-Moneim AS. Neuropsychiatric symptoms in post-COVID-19 long haulers. Acta Neuropsychiatr. 2022;34:318–29. https://doi.org/10.1017/neu.2022.13.
Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706–14. https://doi.org/10.1038/s41591-022-01909-w.
Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J Med Virol. 2022;94:253–62. https://doi.org/10.1002/jmv.27309.
Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593–607. https://doi.org/10.1093/infdis/jiac136.
Luo J, Zhang J, Tang HT, Wong HK, Lyu A, Cheung CH, et al. Prevalence and risk factors of long COVID 6–12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong. J Med Virol. 2023;95: e28862. https://doi.org/10.1002/jmv.28862.
Jassat W, Mudara C, Vika C, Welch R, Arendse T, Dryden M, et al. A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. Int J Infect Dis. 2023;128:102–11. https://doi.org/10.1016/j.ijid.2022.12.036.
Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373: n1098. https://doi.org/10.1136/bmj.n1098.
Fernández-de-Las-Peñas C, Pellicer-Valero OJ, Navarro-Pardo E, Palacios-Ceña D, Florencio LL, Guijarro C, et al. Symptoms experienced at the acute phase of SARS-CoV-2 infection as risk factor of long-term post-COVID symptoms: the LONG-COVID-EXP-CM multicenter study. Int J Infect Dis. 2022;116:241–4. https://doi.org/10.1016/j.ijid.2022.01.007.
Cristillo V, Pilotto A, Cotti Piccinelli S, Bonzi G, Canale A, Gipponi S, et al. Premorbid vulnerability and disease severity impact on long-COVID cognitive impairment. Aging Clin Exp Res. 2022;34:257–60. https://doi.org/10.1007/s40520-021-02042-3.
Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19:12422. https://doi.org/10.3390/ijerph191912422.
García-Abellán J, Fernández M, Padilla S, García JA, Agulló V, Lozano V, et al. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol. 2022;13: 920627. https://doi.org/10.3389/fimmu.2022.920627.
Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun. 2022;13:446. https://doi.org/10.1038/s41467-021-27797-1.
Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity. J Allergy Clin Immunol Pract. 2019;7:1763–70. https://doi.org/10.1016/j.jaip.2019.02.004.
Tangye SG, COVID Human Genetic Effort consortium. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. J Allergy Clin Immunol. 2023;151:818–31. https://doi.org/10.1016/j.jaci.2022.11.010.
Giardino G, Milito C, Lougaris V, Punziano A, Carrabba M, Cinetto F, et al. The impact of SARS-CoV-2 infection in patients with inborn errors of immunity: the experience of the Italian Primary Immunodeficiencies Network (IPINet). J Clin Immunol. 2022;42:935–46. https://doi.org/10.1007/s10875-022-01264-y.
Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol. 2021;147:870-875.e1. https://doi.org/10.1016/j.jaci.2020.12.620.
Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42:1508–20. https://doi.org/10.1007/s10875-022-01352-z.
Milito C, Firinu D, Bez P, Villa A, Punziano A, Lagnese G, et al. A beacon in the dark: COVID-19 course in CVID patients from two European countries: different approaches, similar outcomes. Front Immunol. 2023;14:1093385. https://doi.org/10.3389/fimmu.2023.1093385.
Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Allergy Clin Immunol Pract. 2021;9:2904-2906.e2. https://doi.org/10.1016/j.jaip.2021.04.017.
ESID - European Society for Immunodeficiencies [Internet]. Available from: https://esid.org/Working-Parties/Registry-Working-Party/. Accessed 22 Dec 2023
Sanità E-IS di. EpiCentro [Internet]. Available from: https://www.epicentro.iss.it/. Accessed 22 Dec 2023
Bergna A, Lai A, Ventura CD, et al. Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy in 2020 and 2022 period. Authorea Preprints; 2023. https://doi.org/10.22541/au.168931270.03874429/v1.
Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al. Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts. J Allergy Clin Immunol. 2012;130:1197-1198.e9. https://doi.org/10.1016/j.jaci.2012.05.046.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7. https://doi.org/10.1016/S1473-3099(20)30483-7.
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7. https://doi.org/10.1016/S1473-3099(21)00703-9.
Long COVID - household pulse survey - COVID-19 [Internet]. Available from: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. Accessed 22 Dec 2023
Yazdani R, Habibi S, Sharifi L, Azizi G, Abolhassani H, Olbrich P, et al. Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management. J Investig Allergol Clin Immunol. 2020;30:14–34. https://doi.org/10.18176/jiaci.0388.
Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562-571.e1. https://doi.org/10.1016/j.anai.2022.06.009.
Wang C, Ramasamy A, Verduzco-Gutierrez M, Brode WM, Melamed E. Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants. Virol J. 2023;20:124. https://doi.org/10.1186/s12985-023-02061-8.
Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210–6. https://doi.org/10.1038/s41590-021-01113-x.
Hajjar J, Guffey D, Minard CG, Orange JS. Increased incidence of fatigue in patients with primary immunodeficiency disorders: prevalence and associations within the US Immunodeficiency Network Registry. J Clin Immunol. 2017;37:153–65. https://doi.org/10.1007/s10875-016-0367-1.
Wu JY, Liu MY, Hung KC, Hsu WH, Tsai YW, Liu TH, et al. Nutritional deficiency anemia and post-acute sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: a six-month retrospective cohort analysis of 30 892 patients. J Med Virol. 2023;95(11): e29246. https://doi.org/10.1002/jmv.29246.
de Lollo C, de MoraesVasconcelos D, da Silva Oliveira LM, Domingues R, de Carvalho GC, da Silva Duarte AJ, et al. Chemokine, cytokine and type I interferon production induced by Toll-like receptor activation in common variable immune deficiency. Clin Immunol Orlando Fla. 2016;169:121–7. https://doi.org/10.1016/j.clim.2016.07.001.
Tang K-T, Hsu B-C, Chen D-Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12: 645013. https://doi.org/10.3389/fimmu.2021.645013.
Leon L, Perez-Sancristobal I, Madrid A, Lopez-Pedraza L, Colomer JI, Lerma S, et al. Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases. Rheumatol Adv Pract. 2022;6:rkac008. https://doi.org/10.1093/rap/rkac008.
Boekel L, Atiqi S, Leeuw M, Hooijberg F, Besten YR, Wartena R, et al. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands. Lancet Rheumatol. 2023;5:e375–85. https://doi.org/10.1016/S2665-9913(23)00127-3.
Ahn SH, Kim JL, Kim JR, Lee SH, Yim HW, Jeong H, et al. Association between chronic fatigue syndrome and suicidality among survivors of Middle East respiratory syndrome over a 2-year follow-up period. J Psychiatr Res. 2021;137:1–6. https://doi.org/10.1016/j.jpsychires.2021.02.029.
Rivalta B, Amodio D, Milito C, Chiriaco M, Di Cesare S, Giancotta C, et al. Case report: ebv chronic infection and lymphoproliferation in four APDS patients: the challenge of proper characterization, therapy, and follow-up. Front Pediatr. 2021;27(9): 703853. https://doi.org/10.3389/fped.2021.703853.
Allain V, Grandin V, Meignin V, Bertinchamp R, Boutboul D, Fieschi C, Galicier L, et al. Lymphoma as an exclusion criteria for CVID diagnosis revisited. J Clin Immunol. 2023;43(1):181–91. https://doi.org/10.1007/s10875-022-01368-5.
von Spee-Mayer C, Echternach C, Agarwal P, Gutenberger S, Soetedjo V, Goldacker S, et al. Abatacept use is associated with steroid dose reduction and improvement in fatigue and CD4-dysregulation in CVID patients with interstitial lung disease. J Allergy Clin Immunol Pract. 2021;9:760-770.e10. https://doi.org/10.1016/j.jaip.2020.10.028.
Pulvirenti F, Cinetto F, Milito C, Bonanni L, Pesce AM, Leodori G, et al. Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8(6):1894-1899.e2. https://doi.org/10.1016/j.jaip.2020.04.003.
Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2023;64:66–74. https://doi.org/10.1007/s12016-021-08848-3.